Aspirin and colorectal cancer according to the U.S. Preventive Services Task Force (USPSTF):
For the prevention colorectal cancer in individuals at average risk for colorectal cancer the recommends against the routing use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs). According to the USPSTF, aspirin is required in higher doses than cardiovascular and ischemic stroke prevention. The higher doses of aspirin and NSAIDs required to prevent polyps and colorectal cancer poses a risk of severe bleeding episodes. Therefore, the USPSTF has determined that the risk of hemorrhagic stroke with aspirin outweighs the benefit of colorectal cancer prevention. The risk of gastrointestinal bleeding and hemorrhage with NSAIDs outweigh the benefits of colorectal cancer prevention. (4)